Please assess the completion status of the following clinical trial:

Trial Title: Angel® Catheter Early Feasibility Clinical Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
INCLUSION CRITERIA (Must Answer YES to all Inclusion Criteria):~1. Subject or legally authorized representative is willing and able to provide written informed consent, AND~2. Subject is 18 years or older, AND~3. Subject is currently admitted OR to be admitted to the Intensive Care Unit (ICU) within ≤36 hours of screening, AND~4. Subject has a clinical need for a Central Venous Catheter, and/or the subject has an existing Central Venous Catheter that has been in place for \<36 hours before Angel® Catheter placement, AND~5. Subject is considered at high risk for PE and meets ONE of the following criteria:~   1. Subject has multiple trauma with at least ONE of the following:~      * Severe head injury~     * Head injury with a long bone fracture~     * Spinal cord injury with paraplegia or quadriplegia~     * Multiple (≥2) long bone fractures~     * Multiple (≥2) long bone fractures with pelvic fracture~     * Pelvic fracture requiring open fixation~  2. Critically ill subject in the Intensive Care Unit with at least ONE of the following:~      * Hemorrhagic or ischemic stroke~     * Multiple organ failure~     * Active or recent bleeding (within the past 2 weeks)~     * Severe sepsis~     * Lower extremity DVT~     * Anticipated ventilator requirement of greater than one week~  3. Critically ill subject requiring temporary (≥48 hours) interruption of medical thromboprophylaxis (prophylactic anticoagulation)~EXCLUSION CRITERIA (Must Answer NO to All Exclusion Criteria):~1. Subject is pregnant or lactating~2. BMI = (Weight (lb) x 703)/(〖Height〗\^2 (inches)) \> 45; BMI may also be calculated at http://nhlbisupport.com/bmi/bminojs.htm~3. Subject has a pre-existing IVC filter in place~4. Subject is currently receiving prophylactic anticoagulation, other than aspirin or Plavix. Specifically, the subject is receiving any of the following medications: heparin, low molecular weight heparin, factor Xa inhibitors (i.e. xabans), Coumadin, and thrombin inhibitors.~5. Subject has a diagnosis of pulmonary embolism~6. Subject is participating in another clinical investigation~7. Subject has known hypersensitivity to any of the components of the Angel® Catheter, specifically Nitinol (nickel and/or titanium)~8. Subject has functioning pelvic renal allograft on the only side available for device insertion~9. Subject has undergone a surgical procedure involving the femoral vein or pelvic veins through which the device must be inserted~10. Anatomic inability to place the Angel® Catheter (including a history of thrombosis of venous system on side of proposed access)~11. Anticipated survival ≤48 hours

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Angel® Catheter (Type: EXPERIMENTAL): All eligible subjects will receive an Angel® Catheter.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval